Revvity (RVTY) free cash flow

Free cash flow · fiscal 2025
$509.41M

Revvity (RVTY) generated free cash flow of $509.41M in fiscal 2025 (the year ended December 31, 2025). That is 6.0% lower than the $541.65M of fiscal 2024. Figures as of 18 Nov 2026, 12:05 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$509.41M
Change on fiscal 2024
−6.0%
Highest on record
$1.32Bfiscal 2022
Lowest on record
$9.90Mfiscal 2023
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Revvity free cash flow, in more detail

Across the 18 fiscal years on record (2008–2025), the highest was $1.32B in fiscal 2022 and the lowest $9.90M in fiscal 2023.

History · 18 fiscal years

Free cash flow by fiscal year

Revvity free cash flow, year by year

Revvity (RVTY) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$509.41M 6.0% down
2024$541.65M 5,369.0% up
2023$9.90M 98.3% down
2022$594.18M—
2022$1.32B 59.9% up
2021$828.54M—
2019$287.14M 31.8% up
2018$217.79M 12.7% down
2017$249.36M—
2017$318.91M 23.2% up
2016$258.88M—
2014$254.45M 112.7% up
2013$119.61M 9.0% up
2012$109.77M—
2012$194.28M 48.8% up
2011$130.61M 6.0% up
2010$123.21M—
2008$182.58M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Revvity and comparable companies
CompanyFree cash flowFiscal year
Medpace Holdings MEDP$681.87M2025
Revvity RVTY$509.41M2025
Exelixis EXEL$844.34M2025
Charles River Laboratories International CRL$518.49M2025
Neurocrine Biosciences NBIX$748.70M2025
Ascendis Pharma ASND€45.41M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RVTY

Revvity, figure by figure

Revvity (RVTY) overview: price, valuation and scorecardAll health care companies by market value

Revvity free cash flow: questions and answers

What is Revvity's free cash flow?

Revvity (RVTY) generated free cash flow of $509.41M in fiscal 2025 (the year ended December 31, 2025). That is 6.0% lower than the $541.65M of fiscal 2024.

What are the highest and lowest free cash flow figures on record for Revvity?

Across the 18 fiscal years on record (2008–2025), the highest was $1.32B in fiscal 2022 and the lowest $9.90M in fiscal 2023.

How is Revvity's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Revvity it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Revvity (RVTY) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/RVTY/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.